AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
239.76
-1.78 (-0.74%)
Products, Regulatory

Amgen Announces Approval Of Aimovig In Japan For Suppression Of Onset Of Migraine Attacks In Adults

Published: 06/23/2021 08:15 GMT
AMGEN Inc. (AMGN) - Amgen Announces Approval of Aimovig® (erenumab) in Japan for Suppression of Onset of Migraine Attacks in Adults.
Amgen- Approval is Based on Results From Phase Ii Study Evaluating Safety and Efficacy of Aimovig in Adult Japanese Patients With Episodic Migraine.
Amgen-approval Based on Results From Phase Iii Study Evaluating Efficacy, Safety of Aimovig in Adult Japanese Patients With Episodic, Chronic Migraine.